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My coming here to Richmond 
to discuss immunosuppressive 
drugs is surely carrying coals to 
Newcastle, because the Medical 
College of Virginia has been a 
leader in this field, particularly with 
reference to transplantation of the 
kidney. I don't know what I can 
tell you that you already don't know 
about immunosuppression; never-
theless, you might be interested in 
learning of our own experience 
with these drugs. 
The four main classes of cyto-
toxic drugs of interest to the im-
munologist are the alkylating agents 
such as nitrogen mustard and cy-
clophosphamide, purine antagonists 
( 6-mercaptopurine and azathio-
prine), the pyrimidine antagonists 
such as 5-fluorouracil, and finally 
the extremely interesting and po-
tentially versatile agent methotrex-
ate, a folic acid analog. Our labora-
tory has chosen to focus its 
attention on a single class of these 
compounds, the purine antagonists, 
in an attempt to find out as much 
about their immunological proper-
ties as we can. I plan to discuss two 
aspects of this work: 1) Some of 
the effects of 6-mercaptopurine (6-
MP) in experimental animals, and 
2) some of the effects of its ana-
logue, azathioprine, in man. 
Purine Antagonists 
6-Mercaptopurine, a rather sim-
ple analogue of hypoxanthine, has 
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very powerful effects on cellular 
metabolism. Azathioprine was syn-
thesized with the hope that it would 
have a higher therapeutic index 
than the parent compound. Its imi-
dazol ring was attached to the sul-
fur atom in the expectation that 
this would slow down the metabolic 
degradation of 6-MP. Azathioprine 
does in fact appear to have a higher 
therapeutic index when compared 
to 6-MP in mice, but this has not 
yet been established in man. 
6-Mercaptopurine has two major 
immunological properties that can 
be demonstrated in experimental 
animals. The first of these is sup-
pression of humoral antibody syn-
thesis. Animals given only a one-
week course of 6-MP fail to 
elaborate a normal primary im-
mune response. The second major 
effect of this material is on trans-
plantation immunity; a significant 
prolongation of homograft survival 
can be obtained in a variety of ani-
mals treated with 6-MP. 
One of the fundamental prob-
lems in this field , in fact the prob-
lem which I believe to be central 
to rational and successful immuno-
suppressive drug therapy, is that 
despite the very specific biochemi-
cal sites of action of various anti-
metabolites, the final result in an 
organized cell is its death. Regard-
less how specific the biochemical 
effect of an antimetabolite may be, 
the end result is disintegration of 
the metabolic cycles of the cell. 
Therefore, the central question is 
whether any specific immunologi-
cal effects can be obtained by the 
use of materials which are really 
cell poisons. In my view, it is 
worthless to pursue a generalized 
destruction of the immune capa-
bility of an individual in or-
der to achieve immunosuppression, 
whether in the treatment of an im-
munological disease or in the estab-
lishment of a functioning tissue 
graft. We would be trading a pos-
sible clinical effect for an immuno-
logical cripple. 
Immunological Effects of 
Cytotoxic Drugs 
Quite surprisingly, specific im-
munological effects can in fact be 
obtained by cytotoxic drugs. De-
pending upon the experimental de-
sign, it is possible to delete a 
specific immunological reactivity 
without affecting an immune re-
sponse to a randomly selected anti-
gen. Such an animal is not an 
immunological cripple. It has ac-
quired immunological tolerance of 
an antigen used during the period 
of chemotherapy. If this can be 
obtained in an experimental ani-
mal, there is every reason to be-
lieve that it can be also achieved 
in man. 
One other effect of 6-mercapto-
purine, and probably of other 
agehts, which · is of considerable 
importance in attempting to assess 
the reason for their clinical effec-
tiveness, is iJJustrated by experi-
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ments on suppression of the Arthus 
reaction in hyperimmunized rab-
bits. In these animals the peripheral 
expression of immune injury has 
been eliminated without an effect 
on the synthesis of antibody. Or, 
to put it differently, 6-MP has, in 
addition to its capacity to suppress 
antibody synthesis, a very potent 
anti-inflammatory effect. This will 
be seen time and again in clinical 
material. 
Mechanism of Action of 
Cytotoxic Drugs 
The mechanism of action of 
these drugs in patients with dis-
eases presumed to be on an im-
munological basis is far from clear. 
Some of the questions we have 
posed include: 1) Does immuno-
suppression in fact occur in pa-
tients treated with these agents? 
2) Can selective immunosuppres-
sion be achieved in man? 3) Is 
there any correlation between the 
degree of immunosuppression 
achieved with these agents and the 
clinical response? In order to gain 
some insight into these questions, 
the immune responses of a group 
of patients treated with either aza-
thioprine or amethopterin were 
measured . Keyhole limpet hemo-
cyanin (KLH), a powerful antigen 
long used in experimental animals, 
but never before applied to the 
study of human immunity, was 
used to evaluate the primary re-
sponse. In normal subjects it pro-
vokes both a circulating antibody 
response and classical delayed hy-
persensitivity. Diphtheria toxoid 
was used to study the secondary 
response. In about a third of the 
patients, both primary and sec-
ondary immune responses were 
completely ablated during chemo-
therapy. In another third of the 
patients the primary immune re-
sponse was completely suppressed, 
but a relatively normal secondary 
immune response occurred. An-
other third of the patients had a 
most interesting type of immune 
response while on continuous or 
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even intermittent drug therapy. 
This can be called the "accordion" 
effect. When compared to the nor-
mal immune response, the induc-
tion period is greatly prolonged. 
However, once antibody synthesis 
occurs, there is a very rapid burst 
of antibody formation. This occurs 
even while the patient is on con-
tinuous immunosuppressive drug 
treatment. 
One of the interesting observa-
tions that came out of this study 
was the effect of these drugs on 
two classes of immunoglobulins, 
IgM and JgG. In two-thirds of the 
patients on immunosuppressive 
drug therapy a greatly prolonged, 
but quantitatively normal IgM re-
sponse occurred in the absence of 
any detectable lgG antibody syn-
thesis. Thus, an apparently selec-
tive suppression of one molecular 
class of antibody may be obtained 
with both azathioprine and metho-
trexate in man. 
Clinical Results 
The question whether continuous 
immunosuppression is required to 
maintain a clinical remission in pa-
tients with immunological diseases 
probably has a negative answer in 
light of the "accordion" effect men-
tioned previously. This is another 
reason for believing that treatment 
with the currently available im-
munosuppressive drugs need be 
pushed to the point of destruction 
of all immune capabilities of the 
patient. 
The third question, is there any 
correlation between the degree of 
immunosuppression and the actual 
clinical result, is extremely difficult 
to answer. In many patients there 
is no such correlation. Extensive 
depression of immunity does not 
indicate that a patient will respond 
clinically. Furthermore, some pa-
tients with a minimum or no im-
munosuppression have dramatic im-
provements. We believe that many 
of the effects of antimetabolites 
we have seen in man. may be 




In conclusion, the antimetabo-
lites have proven extremely inter-
esting in the laboratory for the 
exploration of the mechanism of 
antibody synthesis and related 
problems. They have also proven 
to be extremely useful and inter-
esting materials in the clinic. 
Whether they are going to replace 
any other standard forms of ther-
apy, such as the corticosteroids, is, 
in my view, doubtful. Their use at 
the moment is experimental and 
their ultimate place in clinical med-
icine is by no means settled. They 
appear to have two important 
effects in man: 1) Suppression of 
antibody formation which can be, 
in many individuals, selective; and 
2) Very important anti-inflamma-
tory properties which may account 
for their effects on immune injury 
and for some of the very rapid re-
sponses seen in individuals treated 
with these agents. 
81 
